Lisanti Capital Growth LLC Has $4.18 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Lisanti Capital Growth LLC increased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 57.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,010 shares of the biotechnology company's stock after acquiring an additional 14,225 shares during the period. Lisanti Capital Growth LLC owned approximately 0.21% of Ligand Pharmaceuticals worth $4,180,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Barclays PLC grew its stake in shares of Ligand Pharmaceuticals by 20.0% in the 3rd quarter. Barclays PLC now owns 43,456 shares of the biotechnology company's stock worth $4,349,000 after purchasing an additional 7,247 shares during the last quarter. Geode Capital Management LLC grew its position in Ligand Pharmaceuticals by 5.5% in the third quarter. Geode Capital Management LLC now owns 428,270 shares of the biotechnology company's stock worth $42,874,000 after buying an additional 22,495 shares during the last quarter. Fisher Asset Management LLC increased its holdings in shares of Ligand Pharmaceuticals by 12.4% in the third quarter. Fisher Asset Management LLC now owns 59,574 shares of the biotechnology company's stock valued at $5,963,000 after buying an additional 6,555 shares in the last quarter. Yousif Capital Management LLC lifted its position in shares of Ligand Pharmaceuticals by 1.4% during the 4th quarter. Yousif Capital Management LLC now owns 7,193 shares of the biotechnology company's stock valued at $771,000 after acquiring an additional 96 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Ligand Pharmaceuticals by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 163,924 shares of the biotechnology company's stock worth $16,407,000 after acquiring an additional 8,584 shares in the last quarter. 91.28% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on LGND shares. StockNews.com downgraded Ligand Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday. Benchmark reaffirmed a "buy" rating and set a $135.00 price objective on shares of Ligand Pharmaceuticals in a research note on Monday, December 23rd. Barclays raised their target price on shares of Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an "overweight" rating in a report on Monday, December 16th. Royal Bank of Canada boosted their price target on shares of Ligand Pharmaceuticals from $141.00 to $143.00 and gave the company an "outperform" rating in a report on Wednesday, December 11th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Ligand Pharmaceuticals in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to MarketBeat.com, Ligand Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $147.00.

Ligand Pharmaceuticals Price Performance

LGND traded down $3.51 on Tuesday, reaching $105.79. 171,290 shares of the company traded hands, compared to its average volume of 124,433. Ligand Pharmaceuticals Incorporated has a 52-week low of $67.72 and a 52-week high of $129.90. The company has a market cap of $2.04 billion, a price-to-earnings ratio of 42.15 and a beta of 1.12. The stock's 50 day moving average price is $114.37 and its 200-day moving average price is $111.68.

Insider Activity

In other Ligand Pharmaceuticals news, CFO Octavio Espinoza sold 5,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $115.03, for a total value of $575,150.00. Following the transaction, the chief financial officer now owns 18,879 shares in the company, valued at $2,171,651.37. The trade was a 20.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.90% of the stock is currently owned by corporate insiders.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.